英语翻译H Kunitoh*,1 and K Suzuki21Department of Internal Medici

英语翻译
H Kunitoh*,1 and K Suzuki2
1Department of Internal Medicine and Thoracic Oncology,National Cancer Center Hospital,5-1-1 Tsukiji,Chuo-ku,Tokyo 104-0045,Japan;
2Department of Thoracic Surgery,National Cancer Center Hospital,5-1-1 Tsukiji,Chuo-ku,Tokyo 104-0045,Japan
The trimodality approach represented by concurrent chemoradiotherapy followed by surgical resection is a highly effective,but
potentially toxic therapy for locally advanced non-small-cell lung cancer (NSCLC).In this review,we discuss the current status of this
therapy in patients with mediastinal node-positive (N2) stage III NSCLC or superior sulcus tumor,and present an overview of the
principles for optimisation of the risk/benefit.Numerous clinical questions remain,and enrolment of patients into well-designed
clinical trials should be encouraged.
British Journal of Cancer (2007) 96,1498–1503.doi:10.1038/sj.bjc.6603751 www.bjcancer.com
Published online 1 May 2007
& 2007 Cancer Research UK
Keywords:trimodality; preoperative chemoradiotherapy; stage III NSCLC; superior sulcus tumour
_________________________________
Lung cancer is the leading cause of death from cancer in Japan as
well as in other industrialised nations.Non-small-cell lung cancer
(NSCLC) accounts for about 80% of all cases.
About one-third of all cases of NSCLC present with locally
advanced,stage IIIA/IIIB disease,most frequently with mediastinal
node involvement (N2).Surgical resection was employed as
‘standard’ therapy for relatively less advanced ‘resectable’ cases
with N2 NSCLC; however,the prognosis was not favourable
(Suzuki et al,1999).For more advanced,‘bulky’ unresectable N2
disease,neither satisfactory local control nor satisfactory suppression
of micrometastases was achieved with definitive thoracic
radiotherapy (Schaake-Koning et al,1992; Dillman et al,1996).
Systemic chemotherapy was introduced two decades ago for
cases with stage III N2 NSCLC (Le Chevalier et al,1991; Schaake-
Koning et al,1992; Sause et al,1995; Dillman et al,1996),aimed at
both eradication of micrometastases and improvement of local
control.A multimodality approach to treatment,for example,

（医科专业词汇）和（医科专业词汇）
1、国立癌症中心医院内科和胸肿瘤科,位于日本东京104-0045区绰辜路5-1-1栋；
2、国立癌症中心医院胸外科,位于日本东京104-0045区绰辜路5-1-1栋；
日本针灸办法派化疗其次是手术切除是一个非常有效的,但潜在有毒治疗局部晚期非小细胞肺癌（非小细胞肺癌） .在此检讨过程中,我们讨论的现状,这治疗纵隔淋巴结阳性（ n2 ）的第三阶段的非小细胞肺癌或上沟肿瘤,并在发言中概述了原则通过优化风险/受益.众多的临床问题仍未解决,和入学的病人到设计良好临床试验的,应予以鼓励.
英国癌症杂志（ 2007 ） 96 ,1498年至1503年.内务部：10.1038/sj.bjc.6603751 www.bjcancer.com
出版在线2007年5月1日
2007年英国癌病研究
关键词：trimodality ;术前化疗;第三阶段的非小细胞肺癌;优于沟肿瘤
肺癌是导致死亡的主要原因,从癌症在日本以及在其他工业化国家.非小细胞肺癌（肺癌）占80 ％左右的所有情况.大约有三分之一的所有案件,目前非小细胞肺癌局部先进的,iiia期/第三b疾病,最常见的纵隔节点参与（氮气） .手术切除是受雇为'标准'治疗相对较不先进'切除'例与氮气非小细胞肺癌,但预后并不有利（铃木等人,1999年） .为更先进的,'粗大'不能氮气
疾病,既不是满意的局部控制,也没有令人满意的镇压
微达到确切的胸放疗（ schaake - koning等人,1992年;迪尔曼等,1996 ） .
全身化疗是推出了两项几十年前为例进行第三阶段的氮气非小细胞肺癌（乐富安等人,1991年; schaake -
koning等人,1992年; sause et al ,1995年;迪尔曼等,1996 ） ,其目的是既消除微和改进地方
控制.一多学科综合的方法来治疗,例如...